Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much as
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · energy
- [ENERGY] Two Nuclear Wrongs Don’t Make a Right
- [ENERGY] Alemania dice que mientras haya gestos de amenaza nuclear hará falta "disuasión creíble"
- [ENERGY] Iran proposal suggests lifting Strait blockade without nuclear deal
- [ENERGY] He had a little setback…
- [ENERGY] Watching a Folder in Rust with notify-rs — Hot Folder for PDF Automation
- [ENERGY] Meta gains early access to 1 GW of space-based solar power